Create a narrative

Laboratorios Farmaceuticos Rovi Community

BME:ROVI Community

1 Narratives written by author
0 Comments on narratives written by author
42 Fair Values set on narratives written by author

Create a narrative

Laboratorios Farmaceuticos Rovi

AN

AnalystConsensusTarget

Consensus Narrative from 8 Analysts

Okedi Expansion And Heparin Integration To Boost Revenue And Net Margins

Key Takeaways Focus on Okedi and enoxaparin indicates potential revenue growth and improved profit margins from European development and heparin sales volume. Expansion and investment in CDMO and heparin production aim to boost revenue, enhance efficiency, and improve earnings per share.

€80.14

FV

32.7% undervalued

8.25%

Revenue growth p.a.

1

0

20

5 days ago